Eicosanoids and Their Drugs in Cardiovascular Diseases: Focus on Atherosclerosis and Stroke

Valérie Capra, Magnus Bäck, Silvia S. Barbieri, Marina Camera, Elena Tremoli, G. Enrico Rovati

Research output: Contribution to journalArticle

Abstract

Eicosanoids are biologically active lipids in both physiologic and pathophysiologic situations. These mediators rapidly generate at sites of inflammation and act through specific receptors that following the generation of a signal transduction cascade, lead to coordinated cellular responses to specific stimuli. Prostanoids, that is, prostaglandins and thromboxane A2, are active products of the cyclooxygenase pathway, while leukotrienes and lipoxins derive from the lipoxygenase pathway. In addition, a complex family of prostaglandin isomers called isoprostanes is derived as free-radical products of oxidative metabolism. While there is a wide consensus on the importance of the balance between proaggregating (thromboxane A2) and antiaggregating (prostacyclin) cyclooxygenase products in cardiovascular homeostasis, an increasing body of evidence suggests a key role also for other eicosanoids generated by lipoxygenases, epoxygenases, and nonenzymatic pathways in cardiovascular diseases. This intricate network of lipid mediators is unique considering that from a single precursor, arachidonic acid, may derive an array of bioproducts that interact within each other synergizing or, more often, behaving as functional antagonists.

Original languageEnglish
Pages (from-to)364-438
Number of pages75
JournalMedicinal Research Reviews
Volume33
Issue number2
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Thromboxane A2
Eicosanoids
Prostaglandin-Endoperoxide Synthases
Prostaglandins
Atherosclerosis
Cardiovascular Diseases
Stroke
Lipoxygenases
Lipoxins
Isoprostanes
Lipids
Lipoxygenase
Leukotrienes
Epoprostenol
Arachidonic Acid
Pharmaceutical Preparations
Free Radicals
Signal Transduction
Homeostasis
Inflammation

Keywords

  • Cardiovascular disease
  • Eicosanoids
  • Leukotrienes
  • Lipoxins
  • Prostanoids

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Pharmacology

Cite this

Eicosanoids and Their Drugs in Cardiovascular Diseases : Focus on Atherosclerosis and Stroke. / Capra, Valérie; Bäck, Magnus; Barbieri, Silvia S.; Camera, Marina; Tremoli, Elena; Rovati, G. Enrico.

In: Medicinal Research Reviews, Vol. 33, No. 2, 03.2013, p. 364-438.

Research output: Contribution to journalArticle

@article{2fdf0970291b46399cb429b7a47b6e06,
title = "Eicosanoids and Their Drugs in Cardiovascular Diseases: Focus on Atherosclerosis and Stroke",
abstract = "Eicosanoids are biologically active lipids in both physiologic and pathophysiologic situations. These mediators rapidly generate at sites of inflammation and act through specific receptors that following the generation of a signal transduction cascade, lead to coordinated cellular responses to specific stimuli. Prostanoids, that is, prostaglandins and thromboxane A2, are active products of the cyclooxygenase pathway, while leukotrienes and lipoxins derive from the lipoxygenase pathway. In addition, a complex family of prostaglandin isomers called isoprostanes is derived as free-radical products of oxidative metabolism. While there is a wide consensus on the importance of the balance between proaggregating (thromboxane A2) and antiaggregating (prostacyclin) cyclooxygenase products in cardiovascular homeostasis, an increasing body of evidence suggests a key role also for other eicosanoids generated by lipoxygenases, epoxygenases, and nonenzymatic pathways in cardiovascular diseases. This intricate network of lipid mediators is unique considering that from a single precursor, arachidonic acid, may derive an array of bioproducts that interact within each other synergizing or, more often, behaving as functional antagonists.",
keywords = "Cardiovascular disease, Eicosanoids, Leukotrienes, Lipoxins, Prostanoids",
author = "Val{\'e}rie Capra and Magnus B{\"a}ck and Barbieri, {Silvia S.} and Marina Camera and Elena Tremoli and Rovati, {G. Enrico}",
year = "2013",
month = "3",
doi = "10.1002/med.21251",
language = "English",
volume = "33",
pages = "364--438",
journal = "Medicinal Research Reviews",
issn = "0198-6325",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Eicosanoids and Their Drugs in Cardiovascular Diseases

T2 - Focus on Atherosclerosis and Stroke

AU - Capra, Valérie

AU - Bäck, Magnus

AU - Barbieri, Silvia S.

AU - Camera, Marina

AU - Tremoli, Elena

AU - Rovati, G. Enrico

PY - 2013/3

Y1 - 2013/3

N2 - Eicosanoids are biologically active lipids in both physiologic and pathophysiologic situations. These mediators rapidly generate at sites of inflammation and act through specific receptors that following the generation of a signal transduction cascade, lead to coordinated cellular responses to specific stimuli. Prostanoids, that is, prostaglandins and thromboxane A2, are active products of the cyclooxygenase pathway, while leukotrienes and lipoxins derive from the lipoxygenase pathway. In addition, a complex family of prostaglandin isomers called isoprostanes is derived as free-radical products of oxidative metabolism. While there is a wide consensus on the importance of the balance between proaggregating (thromboxane A2) and antiaggregating (prostacyclin) cyclooxygenase products in cardiovascular homeostasis, an increasing body of evidence suggests a key role also for other eicosanoids generated by lipoxygenases, epoxygenases, and nonenzymatic pathways in cardiovascular diseases. This intricate network of lipid mediators is unique considering that from a single precursor, arachidonic acid, may derive an array of bioproducts that interact within each other synergizing or, more often, behaving as functional antagonists.

AB - Eicosanoids are biologically active lipids in both physiologic and pathophysiologic situations. These mediators rapidly generate at sites of inflammation and act through specific receptors that following the generation of a signal transduction cascade, lead to coordinated cellular responses to specific stimuli. Prostanoids, that is, prostaglandins and thromboxane A2, are active products of the cyclooxygenase pathway, while leukotrienes and lipoxins derive from the lipoxygenase pathway. In addition, a complex family of prostaglandin isomers called isoprostanes is derived as free-radical products of oxidative metabolism. While there is a wide consensus on the importance of the balance between proaggregating (thromboxane A2) and antiaggregating (prostacyclin) cyclooxygenase products in cardiovascular homeostasis, an increasing body of evidence suggests a key role also for other eicosanoids generated by lipoxygenases, epoxygenases, and nonenzymatic pathways in cardiovascular diseases. This intricate network of lipid mediators is unique considering that from a single precursor, arachidonic acid, may derive an array of bioproducts that interact within each other synergizing or, more often, behaving as functional antagonists.

KW - Cardiovascular disease

KW - Eicosanoids

KW - Leukotrienes

KW - Lipoxins

KW - Prostanoids

UR - http://www.scopus.com/inward/record.url?scp=84873994859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873994859&partnerID=8YFLogxK

U2 - 10.1002/med.21251

DO - 10.1002/med.21251

M3 - Article

C2 - 22434418

AN - SCOPUS:84873994859

VL - 33

SP - 364

EP - 438

JO - Medicinal Research Reviews

JF - Medicinal Research Reviews

SN - 0198-6325

IS - 2

ER -